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Abstract A number of disorders related to cystic fibrosis have
been described since the cloning of the cystic fibrosis gene,
including infertility due to the congenital bilateral absence of the
vas deferens. We have identified, in several patients, complex
cystic fibrosis transmembrane conductance regulator genotypes
like double-mutant alleles. We have now analyzed the structure-
function relationships of one of these mutants, R74W-D1270N
cystic fibrosis transmembrane conductance regulator, expressed
in HeLa cells, to evaluate the contribution of each mutation in
the phenotype. We found that R74W cystic fibrosis transmem-
brane conductance regulator appears to be a polymorphism,
while D1270N cystic fibrosis transmembrane conductance
regulator could be responsible for the congenital bilateral
absence of the vas deferens phenotype. The combination of the
two produced a more severe effect on the chloride conductance
pathway as well as on the phenotype.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Cystic ¢brosis (CF) is the most common severe autosomal
recessive genetic disorder in Caucasians. It is caused by muta-
tions in the cystic ¢brosis transmembrane conductance regu-
lator (CFTR) gene, which encodes a cAMP-regulated chloride
channel [1]. The number of disorders associated with molec-
ular defects in the CFTR gene has increased steadily since the
cloning of the CF gene. These have included male infertility
due to the congenital bilateral absence of the vas deferens
(CBAVD) [2], disseminated bronchiectasis [3], nasal polyposis
[4,5] and, more recently, chronic pancreatitis [6,7]. We and
others have identi¢ed complex CFTR genotypes in these pa-
tients, including double-mutant alleles where two missense
mutations are carried by the same chromosome [8]. It is di⁄-
cult to evaluate the contribution of each mutation or poly-
morphism to the phenotypic expression of these conditions.
We have now investigated the structure-function relation-
ships of one of these mutants, R74W-D1270N-CFTR, using a
heterologous expression system. The ¢rst mutation lies in the
intracellular N-terminus of the CFTR protein and the second
within the second nucleotide binding domain (NBD2), replac-
ing an arginine by a tryptophan at position 74 and an aspartic
acid by an asparagine at position 1270 [9,10]. We postulated
that the switch from a basic hydrophilic residue to a neutral
hydrophobic one (Arg to Trp) would a¡ect the processing of
the CFTR channel in the N-terminus part of the protein and
that the change from a conserved acidic to a neutral residue in
a critical region for channel gating (NBD2) could be delete-
rious. We therefore tested these mutations separately and to-
gether to elucidate the contribution of each mutation to the
phenotype.
The mutant genes were expressed in HeLa cells. We ana-
lyzed the protein biosynthesis by immunoprecipitation and
pulse-chase experiments and chloride channel function by a
halide-sensitive £uorescent dye assay (6-methoxy-N-ethylqui-
nolinium (MEQ)) [11]. This assay was greatly improved by
using a mammalian expression vector that allows visual de-
tection of transfected cells containing the green £uorescent
protein (GFP), which does not alter the function of wild-
type CFTR expressed in HeLa cells. These assays showed
that the R74W mutation should be considered to be a poly-
morphism and suggest that D1270N alone is su⁄cient to pro-
duce the CBAVD phenotype, while the combination of the
two increases the chloride conductance pathway dysfunction
and the phenotype.
2. Materials and methods
2.1. Plasmid construction
A plasmid vector for expressing the human CFTR gene in mamma-
lian cells was constructed by placing the full-length CFTR cDNA
encoding sequence (4.5 kb from nucleotide position 90 to 4578, ob-
tained from pTG5960, a gift from Transgene) in the expression vector
pTracer-CMV (Invitrogen), a vector designed for visual detection of
transfected mammalian cells. The resulting plasmid was designated
pTCFwt. Expression of the CFTR gene in pTCFwt is controlled by
the CMV promoter, while synthesis of the GFP-Zeocin fusion protein
is controlled by the SV40 promoter. Site-directed mutagenesis was
performed on pTCFwt using the GeneEditor kit (Promega).
2.2. Cells culture and transfection
HeLa cells (2.5U105/well) were grown on six well dishes at 37‡C
with 5% CO2 in Dulbecco‘s modi¢ed Eagle‘s medium (DMEM, Glu-
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tamax, Life Technologies) containing 10% fetal calf serum, 100 U/ml
penicillin and 100 g/ml streptomycin (all from Life Technologies).
Con£uent cells (60%) were transfected by lipofection using 8 Wl Lip-
ofectAMINE and 6 Wl Plus reagent (Life Technologies) with 1 Wg of
plasmid according to the manufacturer‘s instructions. Con£uent
monolayers were harvested and used 48 h post-transfection for func-
tional assays, pulse-chase experiments or immunoprecipitation.
2.3. Immunoprecipitation/cAMP-dependent protein kinase (PKA)
assay and pulse-chase experiment
CFTR was immunoprecipitated using the monoclonal antibody
(mAb) 24-1 (Genzyme, Framingham, MA, USA), which recognizes
the C-terminus of CFTR, according to the manufacturer‘s instruc-
tions. Brie£y, cell lysates were prepared with two wells of con£uent
cells and mixed with 0.4 Wg mAb 24-1 and Pansorbin (Calbiochem).
The resulting proteins were phosphorylated in vitro with 5 U of the
catalytic subunit of PKA (Promega) and 10 WCi [Q-33P]ATP (Amer-
sham), separated by 5% SDS-PAGE, dried and autoradiographed.
Pulse-chase experiments were performed by incubating cells for
30 min in DMEM lacking cysteine and methionine and then for
15 min in the same medium containing 100 WCi/ml methionine and
cysteine 35S-labelled (Redivue Pro-mix 35S Amersham). CFTR was
immunoprecipitated from cell homogenates with the mAb 24-1 from
Genzyme and quanti¢ed using a Molecular Dynamics Phospho-
imager.
2.4. MEQ £uorescence assay
Cells were grown on glass coverslips for 24 h and then loaded with
the halide indicator £uorescent dye MEQ as previously described [11].
MEQ £uorescence was excited at 345 nm (¢lter 345/40U, Chroma)
and emitted £uorescence was passed through the dichromatic mirror,
DM 400 nm, and the barrier ¢lter, BA 420 nm (Olympus U-MWB
box). The transfected cells were identi¢ed by visual detection of GFP
£uorescence before starting the MEQ £uorescence measurements.
GFP £uorescence was excited at 440 nm/20U (Chroma) and the
emitted £uorescence was passed through DM 500 nm and BA at
505 nm (Olympus). The cells were incubated at room temperature
for 4 min in hypotonic medium. The medium contained 20 mM
MEQ made by diluting isotonic solution (138 mM NaCl, 2.4 mM
K2HPO4, 0.8 mM KH2PO4, 10 mM HEPES, 1 mM CaSO4, 10 mM
glucose and 20 WM bumetanide (pH 7.4)) 5:1 with water. They were
returned to isotonic bu¡er to recover. 15 min after loading, the cover-
slip was placed in a perfusion chamber, perfused continuously at 37‡C
with the isotonic chloride solution on the stage of an inverted micro-
scope (IX70 Olympus, France) and intracellular MEQ £uorescence
was measured. The chloride solution was replaced with nitrate solu-
tion after 2 min of perfusion. This was identical except that NO33
replaced Cl3. Because nitrate does not interact with MEQ, the £uo-
rescence increases as cell chloride £ows from the cell through the
anion conductive pathways if these pathways are functional in the
plasma membrane. The changes in £uorescence of stimulated (stimu-
latory cocktail: 500 WM 8-(4-chlorophenylthio)-cyclic AMP and 100
WM 3-isobutyl-1-methylxanthine) and unstimulated cells were re-
corded. Excitation was at 350 nm and emission was at s 440 nm.
The £uorescence of single cells was measured with a digital imaging
system and a CCD camera (Gen IV, Prinston Instruments, Trenton,
NJ, USA/Paris, France). Results were analyzed using Meta£uor 3.0
software (Universal Imaging, Media, PA, USA/Paris, France).
The results are expressed as relative £uorescence F/F0, where F is
the change in £uorescence with time and F0 is the minimum £uores-
cence Fig. 3. Cells were scored as positive when the rate of change in
£uorescence with the stimulatory cocktail was greater than that in
basal conditions. We then calculated the slope of the dequenching
curve in basal (vFbasal) and stimulatory (vFstim) conditions and de-
rived the ratio vFstim/vFbasal. This ratio was used rather than the
absolute change in £uorescence as the latter may be in£uenced by
dye loading.
3. Results
3.1. Biochemical characterization of wild-type and mutated
CFTR proteins
HeLa cells were transiently transfected with the gene encod-
ing wild-type and the three mutated CFTR proteins. The
CFTR protein production and function were assessed. The
transfection e⁄ciency was checked by spotting GFP express-
ing cells on the stage of an inverted microscope.
The immunoprecipitation/PKA assay (Fig. 1) showed that
the fully glycosylated form of wild-type CFTR in HeLa cells
showed as a di¡use band of an approximate molecular mass
of 170 kDa (referred to as ‘band C’ [12]) on SDS-PAGE. The
core-glycosylated and non-glycosylated forms were mixed and
appeared as a thin band of about 140 kDa (band A/B) as
expected from our previous study [11]. All three mutant pro-
teins matured completely and the ratio (band C/band
C+B+A = 0.8) was identical, suggesting normal, complete
processing.
The biosynthesis of wild-type and mutated CFTR proteins
was further investigated by pulse-chase experiments (Fig. 2).
The faint band A (non-glycosylated CFTR protein) and band
B (core-glycosylated form) both appeared promptly at H0,
whereas band C (fully glycosylated form) was only detected
after 1 h of chase (H1, Fig. 2A). The mutated proteins had the
same processing time-course as the wild-type CFTR for both
biosynthesis and degradation (data not shown).
Fig. 1. Immunoprecipitation/PKA assay of wild-type and mutant
CFTR proteins using mAb 24-1 (Genzyme).
Fig. 2. Pulse-chase experiment of wild-type CFTR protein using
mAb 24-1 (Genzyme), (A) typical immunoprecipitation of CFTR
protein, (B) quanti¢cation of the amount of band C/band C+B+A.
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3.2. Function of wild-type and mutated CFTR proteins
We tested the cAMP-activated chloride conductance activ-
ity of transfected cells using the MEQ £uorescence assay. Our
assay [11] has been greatly improved by the use of a new
mammalian expression vector. The synthesis of the GFP al-
lowed visual detection of transfected cells, therefore, all cells
analyzed were CFTR-transfected cells. Also, placing the
CFTR cDNA under the control of the human CMV immedi-
ate early promoter resulted in a great gene activity. Both
cDNAs (GFP and CFTR) were contained in the same plasmid
vector, but were placed under di¡erent promoters.
Table 1 summarizes the results of the MEQ £uorescence
assay. None of the mock-transfected cells (pTracer, n = 28)
displayed changes in £uorescence in either basal or cAMP-
stimulated conditions, which are believed to activate the
CFTR chloride channel.
Transiently transfected cells were divided into responsive
and non-responsive cells on the basis of their cAMP-respon-
sive anion conductance. Responsive cells were further divided
into fast (vFstim/vFbasals 5) and slow (vFstim/vFbasal9 5) re-
sponding cells. Most (85%) of the wild-type CFTR-transfected
cells (n = 53) were responsive and 47% of these positive cells
were fast responders (Table 1). The majority (67%) of the
R74W-CFTR cells showed an increased rate of change in
MEQ £uorescence when exposed to the stimulatory cocktail,
indicating activation of a cAMP-dependent anion pathway,
45% of these cells were fast responders. Lastly, 89% of
D1270N-CFTR and 81% of R74W-D1270N-CFTR also had
a cAMP-responsive anion conductance with di¡erent ratios
between fast and slow responding cells (38% fast in
D1270N-CFTR and 24% fast in R74W-D1270-CFTR).
4. Discussion
We have analyzed the structure-function relationships of
three CFTR mutations, R74W, D1270N and the R74W-
D1270N double-mutant, and compared their properties with
those of wild-type CFTR. R74W was ¢rst described in isola-
tion [10], but has since been found in association with
D1270N (Mireille Claustres, personal communication).
D1270N was found in a CBAVD patient bearing the vF508
common mutation on the other allele [9]. Finally, the R74W-
D1270N double-mutant was ¢rst identi¢ed in a compound,
vF508, heterozygote with clinical features of CBAVD, rhini-
tis, recurrent respiratory infections and elevated sweat chlo-
ride concentrations [13]. We have since identi¢ed three unre-
lated patients bearing this complex genotype on one allele,
two CBAVD patients and a 22 year old woman screened
for CFTR mutations because she had severe nasal polyposis.
All three patients had an abnormality in only one copy of the
CFTR gene. The whole encoding sequence was screened to-
gether with the 5T allele, a variant of intron 8 that greatly
reduces the amount of mature CFTR [14], and no other mu-
tation was detected.
To our knowledge, this is the ¢rst reported expression of
the R74W- and/or D1270N-CFTR mutant and the ¢rst func-
tional description of a double-mutant associated with
CBAVD, a disorder related to CF.
The processing of the three mutated CFTR proteins was
normal and similar to that of the wild-type CFTR, given
the presence of the fully glycosylated form of the protein
and the ratio (band C/band C+B+A). This indicates that
they are not class I or II mutations in the classi¢cation pro-
posed by Welsh and Smith [15] (class I mutations produce no
CFTR protein and class II (vF508) fails to mature properly).
Fig. 3. Analysis of the wild-type and mutant CFTR function with
the MEQ £uorescence assay. The sequence of bu¡er changes is indi-
cated in the top inset. The relative £uorescence was measured over
time. HeLa cells were transfected with either wild-type CFTR
(vFstim/vFbasal = 12), R74W-CFTR (vFstim/vFbasal = 11), D1270N-
CFTR (vFstim/vFbasal = 3) or R74W-D1270N-CFTR (vFstim/
vFbasal = 2).
Table 1
Summary of the MEQ assay results
Cell type Wild-type R74W D1270N R74W-D1270N PTracer
Total 53 30 27 26 28
Non-responding 8 10 3 5 28
All responding 45 (85%)a 20 (67%)a 24 (89%)a 21 (81%)a 0
Fast 21 (47%)b 9 (45%)b 9 (38%)b 5 (24%)b 0
vFstim/vFbasal 13.3 þ 6.3c 11.9 þ 8.7c 7.7 þ 2.4c 7.3 þ 2.7c
Range 5.4^26.3 5.9^34 5.6^12.8 5.2^12
Slow 24 (53%)b 11 (55%)b 15 (62%)b 16 (76%)b 0
vFstim/vFbasal 2.7 þ 1.1c 2.5 þ 0.9c 2.8 þ 0.9c 3.2 þ 1.2c
Range 1.3^5 1.1^4.1 1.4^4.5 1.2^4.9
aPercentage of all cells.
bPercentage of positive cells.
cMean values þ S.D.
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Expression of these three mutant genes in HeLa cells
showed that R74W-CFTR, D1270N-CFTR and R74W-
D1270N-CFTR proteins elicited cAMP-dependent chloride
£uxes. R74W-CFTR elicited a cAMP-responsive anion con-
ductance at the same rate as wild-type CFTR. Half of the cells
were fast responders, the other half were slow responders. On
the basis of the results of the functional assay, we postulate
that the R74W mutation is a sequence variation that has no
deleterious e¡ect alone.
D1270N and R74W-D1270N had abnormal responsive pat-
terns. The ratio between fast and slow responder cells was
di¡erent, especially for the double-mutant, since only 24%
of the cells were fast responders. This fraction, as well as
that of D1270N-CFTR (38%), resembles the pattern of re-
sponses of R117H-CFTR, another mild mutant associated
with CBAVD [11]. The substitution is in the second putative
membrane spanning domain of CFTR, the protein is correctly
processed and generates a smaller cAMP-regulated apical
membrane chloride current [16]. The R117H mutation produ-
ces di¡erent phenotypes, depending on the presence or ab-
sence of the 5T allele on the same chromosome [17]. When
R117H occurs on a 5T background, the physiology of the vas
deferens, lungs and sweat glands is impaired, de¢ning a com-
plete but mild CF. When R117H occurs on a 7T background,
only the physiology of the vas deferens is impaired. The
R74W-D1270N double-mutant was associated with a 7T
background in the three patients studied. This implies that
the amount of mutated mRNA synthesized in vivo was nor-
mal. On the other hand, the structure-function analysis per-
formed in vitro showed that the protein is quantitatively and
qualitatively correctly processed to the plasma membrane.
Thus, this double-mutant strongly resembles the R117H mu-
tation when it is associated with the 7T background. We
therefore believe that the R74W-D1270N double-mutant is
responsible for the CBAVD phenotype. The contribution of
each mutant to this phenotype may be as follows: R74W is a
polymorphism which may slightly reduce the normal amount
of CFTR protein (67% of responding cells versus 81^89%) in
vivo and D1270N has a cAMP-responsive anion conductance
with di¡erent ratios between fast and slow responder cells, as
for the R117H mutation. We infer that the combination of
R74W enhances the e¡ect of D1270N by reducing the number
of fast responder cells, as a consequence of the defective reg-
ulation of the R74W-D1270N mutated protein or of a di¡er-
ent turn-over of the protein at the cell surface in vivo. This is
supported by the fact that the compound heterozygote vF508/
D1270N described by Anguiano et al. occurred in a CBAVD
patient with normal sweat sodium and chloride values, i.e.
normal chloride secretion [9], whereas the compound hetero-
zygote vF508/R74W-D1270N described by Casals et al. had a
more severe phenotype and elevated sweat chloride concen-
trations suggesting an abnormal chloride secretion [13].
A recent review by Pilewski and Frizzel [18] pointed out the
importance of the CFTR function for the normal organ func-
tion, underscoring the great susceptibility of the vas deferens
to CFTR mutations. Our results support this observation and
point to the importance of a structure/function analysis of
naturally occurring mutations for understanding how defects
in chloride secretion a¡ect CBAVD patients.
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